AmpliPhi Biosciences (NYSEMKT: APHB) is a biotechnology company focused on the development of a pipeline of naturally occurring viruses called bacteriophages, the natural predators of bacteria. Phages have evolved alongside their bacterial prey; resulting in both precise and highly effective bacterial killing mechanisms.

Phage-based therapy provides a unique and proven approach to treating a wide variety of bacterial infections, in particular, drug-resistant strains of bacteria commonly found in chronically infected patients.

"There are few public health issues of potentially greater importance for society than antibiotic resistance.  It means we are at increasing risk of developing infections that cannot be treated - but resistance can be managed."

Dame Sally Davies, Chief Medical Officer for England, 2013.

Bacteriophages were commonly used prior to the advent of antibiotics in 1940.  However, antibiotic discovery led directly to a decline of phage use.  Phages are still used in parts of Eastern Europe and global interest has revived as antibiotic resistance spreads around the world.

Meanwhile, bacteriophages have continued to enjoy some commercial use, mainly in killing foodborne pathogens.  AmpliPhi's approach is to progress these products through existing regulatory pathways.  We will develop medicines that meet the highest regulatory standards, and that provide an effective and efficient means of killing bacterial infections - especially those that have proven resistant to antibiotics.

Our proprietary development and manufacturing platform allows for the rapid creation of and production of phage-based therapies. We have and continue to identify and develop specific and proprietary phage mixtures to eradicate bacterial infections.

Our discovery and development is initially focused on treatments in areas of great unmet medical need, including:

  • Chronic Rhinosinusitis (CRS) infections related to both:
    • Staphylococcus aureus (S. aureus), including methicillin resistant Staphylococcus aureus (MRSA) and
    • Pseudomonas aeruginosa (P. aeruginosa)
  • Wound and skin infections related to both:
    • S. aureus, including MRSA and
    • P. aeruginosa
  • Chronic lung infections in Cystic Fibrosis patients caused by P. aeruginosa